Twenty percent of patients with AML acquire isocitrate dehydrogenase (IDH) mutations and exhibit increased mitochondrial metabolism, which triggers the abnormal accumulation of α-ketoglutarate and leukemogenesis (Liu and Gong, 2019). Here, IDH1 is linked to acute myeloid leukemia.